autoimmune diseases, and fibrosis. The company is advancing a pipeline of in vivo CAR therapies, including programs for breast cancer, epithelial tumors, and B cell depletion, with several candidates currently in clinical and preclinical development. CREATE Medicines also develops targeted receptor and RNA engineering technologies designed to support repeat dosing and multi-immune cell programming. Its research and clinical efforts are centered on creating scalable immunotherapy approaches that avoid the need for traditional ex vivo cell engineering processes.